Business Wire

EL.EN.

7.9.2022 08:21:35 CEST | Business Wire | Press release

Share
World Stars of Physics Light up Florence

Thanks to the El.En. Group of Calenzano, Florence, a multinational specialized in laser production for medical and industrial applications, and for conservation of artistic heritage, an event was organized to celebrate the just over 40 years since it was founded in the presence of the 2018 Nobel Prize winner for Physics, Gérard Mourou, and other prominent professors of international acclaim who contributed to pioneering research in the field of laser physics, paving the way for a multitude of scientific and medical applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005326/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

G.Mourou, O.Svelto and P.Salvadeo special guest stars at El.En. exclusive event (Photo: Business Wire)

The event was also held to honor two shining stars in the world of physics: The Nobel prize winner Gérard Mourou, who, thanks to the General Manager of El.En., Mr. Paolo Salvadeo, was given the prestigious honor of receiving the Key to the City of Florence from the Mayor of Florence in a separate public ceremony in the afternoon, and Orazio Svelto, Professor Emeritus of Polytechnic of Milan, father of laser in Italy. Prof. Svelto invented the so-called “hollow fiber compressor” making it possible to achieve laser impulses lasting attoseconds, with previously unimaginable peak power. This system is currently used in many laboratories the world over conducting cutting edge scientific research and non-linear spectroscopy.

During the gala dinner in the Salone dei Cinquecento of Palazzo Vecchio, in the presence of the major political authorities, the director of the Uffizi Gallery, of Console USA, and other institutional personalities and of the world of laser, Prof. Mourou shared his vision of the future of science, starting with the studies that earned him his Nobel prize for inventing the so-called Chirped Pulse Amplification (CPA), developed in collaboration with Donna Theo Strickland. It is a technique that, thanks to the generation of ultra-brief and high intensity impulses, has made laser even more versatile and enabled exploration of previously unknown dynamics of physics. A notable presence at the gala dinner was Prof. Sune Svamberg, who for many years was on the Nobel Committee for Physics, two years during which he was president, and Prof. Ursula Keller, one of the most acclaimed and well-known scientists in the world in the field of optoelectronics and photonics.

“It’s an honor and I take great pride in being able to create and maintain a deep connection between the world of academics and industry. This shows how crucial collaboration is between these worlds to conduct studies and make discoveries that improve the people’s quality of life. An osmosis of knowledge and a continuous and stimulating dialog that mark continuity among professors and alumni, many of whom dedicate their daily lives in the company laboratories of our group,” affirmed Paolo Salvadeo, General Manager of the El.En. Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005326/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye